Whitehawk Therapeutics (WHWK) Invested Capital: 2018-2025
Historic Invested Capital for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $157.2 million.
- Whitehawk Therapeutics' Invested Capital rose 128.22% to $157.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.2 million, marking a year-over-year increase of 128.22%. This contributed to the annual value of $52.5 million for FY2024, which is 50.11% down from last year.
- Per Whitehawk Therapeutics' latest filing, its Invested Capital stood at $157.2 million for Q3 2025, which was down 8.66% from $172.1 million recorded in Q2 2025.
- Over the past 5 years, Whitehawk Therapeutics' Invested Capital peaked at $221.7 million during Q1 2025, and registered a low of $35.2 million during Q2 2021.
- Over the past 3 years, Whitehawk Therapeutics' median Invested Capital value was $118.2 million (recorded in 2023), while the average stood at $122.0 million.
- In the last 5 years, Whitehawk Therapeutics' Invested Capital soared by 7,161.64% in 2021 and then slumped by 50.11% in 2024.
- Over the past 5 years, Whitehawk Therapeutics' Invested Capital (Quarterly) stood at $136.7 million in 2021, then climbed by 15.89% to $158.4 million in 2022, then plummeted by 33.58% to $105.2 million in 2023, then plummeted by 50.11% to $52.5 million in 2024, then skyrocketed by 128.22% to $157.2 million in 2025.
- Its last three reported values are $157.2 million in Q3 2025, $172.1 million for Q2 2025, and $221.7 million during Q1 2025.